Quick Answer NP Life Sciences Health Industry Group Inc. reported Total Revenue of $164.6 thousand for fiscal year 2023. NP Life Sciences Health Industry Group Inc. — Key Financials by Year Metric 2023 2022 2021 2020 2019 2018 Total Revenue $164.6K+61.4% $102.0K+191.5% $35.0K+133.3% $15.0K-65.1% $43.0K — Revenue (ASC 606) $164.6K+61.4% $102.0K+191.5% $35.0K+133.3% $15.0K-65.1% $43.0K — … Read more
Quick Answer ACADIA PHARMACEUTICALS INC reported Shares Outstanding of 170.31 million shares for fiscal year 2025. ACADIA PHARMACEUTICALS INC Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 170.31M +2.2% 2024 166.71M +1.3% 2023 164.65M +1.6% 2022 162.06M +0.7% 2021 161.01M +0.9% 2020 159.64M +2.8% 2019 155.28M +7.9% 2018 143.85M +15.6% 2017 … Read more
Quick Answer ACADIA PHARMACEUTICALS INC reported Operating Income of $104.81 million for fiscal year 2025. ACADIA PHARMACEUTICALS INC Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 $104.81M -54.6% 2024 $230.79M +414.5% 2023 -$73.38M +67.2% 2022 -$223.60M -31.2% 2021 -$170.44M +40.5% 2020 -$286.59M -16.2% 2019 -$246.54M +0.4% 2018 -$247.44M +15.4% 2017 -$292.41M … Read more
Quick Answer ACADIA PHARMACEUTICALS INC reported R&D Expense of $328.80 million for fiscal year 2025. ACADIA PHARMACEUTICALS INC R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $328.80M +8.4% 2024 $303.25M -13.8% 2023 $351.62M -2.8% 2022 $361.57M +51.0% 2021 $239.41M -25.0% 2020 $319.13M +32.8% 2019 $240.38M +28.4% 2018 $187.16M +25.5% 2017 $149.19M … Read more
Quick Answer ACADIA PHARMACEUTICALS INC reported Stockholders Equity of $1.23 billion for fiscal year 2025. ACADIA PHARMACEUTICALS INC Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $1.23B +67.5% 2024 $732.79M +69.7% 2023 $431.75M +7.8% 2022 $400.41M -26.0% 2021 $540.89M -13.7% 2020 $627.01M -10.3% 2019 $699.13M +45.9% 2018 $479.08M +42.9% 2017 $335.29M … Read more
Quick Answer ACADIA PHARMACEUTICALS INC reported Cash and Equivalents of $177.69 million for fiscal year 2025. ACADIA PHARMACEUTICALS INC Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $177.69M -44.4% 2024 $319.59M +69.4% 2023 $188.66M +64.3% 2022 $114.85M -22.1% 2021 $147.44M -54.8% 2020 $326.03M +71.9% 2019 $189.68M +40.8% 2018 $134.76M … Read more
Quick Answer ACADIA PHARMACEUTICALS INC reported Diluted EPS of $2.30 per share for fiscal year 2025. ACADIA PHARMACEUTICALS INC Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 $2.30 +69.1% 2024 $1.36 +467.6% 2023 -$0.37 +72.4% 2022 -$1.34 -27.6% 2021 -$1.05 +41.3% 2020 -$1.79 -371.1% 2012 -$0.38 +13.6% 2011 -$0.44 -212.8% 2010 … Read more
Quick Answer ACADIA PHARMACEUTICALS INC reported Total Assets of $1.56 billion for fiscal year 2025. ACADIA PHARMACEUTICALS INC Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $1.56B +31.7% 2024 $1.19B +58.6% 2023 $748.96M +27.4% 2022 $587.81M -16.0% 2021 $700.12M -10.5% 2020 $782.62M -0.1% 2019 $783.18M +45.0% 2018 $540.20M +40.5% 2017 $384.51M … Read more
Quick Answer ACADIA PHARMACEUTICALS INC reported Net Income of $391.00 million for fiscal year 2025. ACADIA PHARMACEUTICALS INC Net Income — Annual History Fiscal Year Net Income YoY Change 2025 $391.00M +72.7% 2024 $226.45M +469.5% 2023 -$61.29M +71.6% 2022 -$215.97M -28.7% 2021 -$167.87M +40.4% 2020 -$281.58M -19.7% 2019 -$235.26M +4.1% 2018 -$245.19M +15.3% 2017 -$289.40M … Read more
Quick Answer ACADIA PHARMACEUTICALS INC reported Revenue (ASC 606) of $1.07 billion for fiscal year 2025. ACADIA PHARMACEUTICALS INC Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2025 $1.07B +11.9% 2024 $957.80M +31.8% 2023 $726.44M +40.4% 2022 $517.24M +6.8% 2021 $484.14M +9.6% 2020 $441.75M +30.3% 2019 $339.08M +51.5% 2018 $223.81M … Read more